Lineage Cell Therapeutics, Inc. Short Interest Up 12.7 percent in July - MarketBeat
| LCTX Stock | USD 0.56 0.01 1.75% |
Slightly above 63% of Lineage Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Lineage Cell Therapeutics suggests that many traders are alarmed. Lineage Cell's investing sentiment can be driven by a variety of factors including economic data, Lineage Cell's earnings reports, geopolitical events, and overall market trends.
Lineage |
Lineage Cell Therapeutics, Inc. Short Interest Up 12.7 percent in July MarketBeat
Read at news.google.com
 |
Lineage Cell Fundamental Analysis
We analyze Lineage Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Lineage Cell is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Lineage Cell Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lineage Cell stock to make a market-neutral strategy. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics with similar companies.
Peers
Lineage Cell Related Equities
| ONTTF | Oxford Nanopore | 1.44 | ||||
| REPL | Replimune | 0.32 | ||||
| NVCT | Nuvectis Pharma | 0.30 | ||||
| SPRO | Spero Therapeutics | 1.28 | ||||
| ICCC | ImmuCell | 2.27 | ||||
| GOSS | Gossamer Bio | 4.07 | ||||
| ARMP | Armata Pharmaceuticals | 4.33 | ||||
| CNTB | Connect Biopharma | 4.40 | ||||
| KRON | Kronos Bio | 5.10 | ||||
| BOLT | Bolt Biotherapeutics | 6.38 | ||||
| NXTC | NextCure | 6.41 | ||||
| OVID | Ovid Therapeutics | 7.55 | ||||
| NUVB | Nuvation Bio | 7.61 | ||||
| PRTG | Portage Biotech | 8.20 | ||||
| CVKD | Cadrenal Therapeutics, | 8.42 | ||||
| LYRA | Lyra Therapeutics | 9.52 | ||||
| MAIA | MAIA Biotechnology | 9.57 | ||||
| CHRS | Coherus BioSciences | 9.91 |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.